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The uveal melanoma (UM) is the most common human intraocular tumour. Simian Virus 40 (SV-40) is a small DNA
tumor virus detected in some malignancies, including the cutaneous melanoma. In this study an indirect ELISA
using synthetic peptides that mimic SV-40 antigens, was employed to detect antibodies against SV-40 in serum
samples from UM patients. Our report indicates a significant higher prevalence of antibodies against SV-40 capsid
protein antigens in serum samples from UM patients compared to controls. Our data suggest an association
between UM and SV-40, indicating that patients affected by uveal melanoma tested SV-40-positive could be
treated by innovative therapies.
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The uveal melanoma (UM) is the most common primary
intraocular tumor. Many studies reported genetic alter-
ations in UM [1], but the causes are poorly understood.
BAP1, a gene encoding a deubiquitinant enzyme, is mu-
tated in several UM cases and in the malignant pleural
mesothelioma (MPM) [2], a human tumour found be as-
sociated with the Simian Virus 40 (SV-40) infection
[3,4]. SV-40 oncogenic potential has been demonstrated
in experimental animals [3,4], while its mutagenic activ-
ities have been detected in different animal and human
cell types [3,4]. In human tumours, SV-40 was identified
for the first time in a patient affected by a cutaneous
melanoma [5], that shares the onset model with UM.
Altogether these data were the background that prompted
us to investigate the association between UM and SV-40 by
analysing the prevalence of SV-40 antibodies in serum
samples from UM affected patients. This study was carried
out, as reported before, by an indirect Enzyme-Linked
Immunosorbent Assay (ELISA) with SV-40 specific* Correspondence: tgm@unife.it; mrf@unife.it
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cross-reactivity with the closely related BKV and JCV which
are obiquitous polyomaviruses in humans [6].
In this investigation, serum samples from UM affected
patients (n = 48) and healthy subjects with ocular nevi
(HSON; n = 71) and without ocular nevi (HS; n = 168),
with the same median age (66 yrs), were analysed for
presence of SV-40 antibodies. All patients and subjects
were vaccinated against the poliomyelitis. The immuno-
logic study was carried out by indirect ELISAs employing
two specific mimotopes from SV-40 viral capsid proteins 1
and 2–3, named B and C peptides, respectively [6]. In our
experiments, serum samples were considered SV-40 VP-
positive upon reacting to both peptides B and C. Informed
written consent was obtained from the patients and sub-
jects. The study was approved by the County Ethical
Committee, Ferrara, Italy.
The overall prevalence, by combining SV-40-positive
sera for both VP1 B and VP2/3 C peptides, in UM pa-
tients was 33%, higher than that detected in HSON or
HS, 17% and 15% respectively. The difference between
UM patients and HSON or HS is statistically significant
(p = 0.038 and p = 0.004, respectively). Serologic profiles
of serum antibody reactivity to SV40 mimotopes are re-
ported in Figure 1. The difference of OD=optical densityLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Serologic profile. Serologic profile of serum antibody
reactivity to SV-40 mimotopes VP1 B (panel A) and VP2/3 C (panel
B) and VPs B + C (panel C). Immunologic data are from patients affected
by UM and from healthy individuals (HS) with and without ocular
nevi. Data are OD values at 405 nm of serum samples diluted 1:20,
detected in indirect ELISA. In scatter dot plotting, each plot represents
the dispersion of OD values to a mean level indicated by the line inside
the scatter with standard error mean (SEM) for each group of subjects
analyzed (Mean OD ± SEM).
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not statistically significant (p > 0.05).
Our immunologic data indicate that a subset (1/3) of
UM is associated with SV-40, a small DNA tumour virus
detected as a contaminant in early anti-polio vaccines
[3,4,7]. At present, SV-40 infection seems to spread in
humans by different ways, including the urine and the
faecal-oral route [3,4,7].
UM onset, like other human cancers, is due to specific
gene mutations. Since SV-40 is oncogenic, clastogenic,
mutagenic and a transforming viral agent [3,7], may be a
risk factor, together with other oncogenic agents such as
the U.V. irradiation, in the UM onset/progression [8].
One may postulate that after infecting the host, SV-40
may exert its tumourigenic potential when the immune
system is impaired. The high prevalence of SV-40 anti-
bodies in sera from UM affected patients is not proof of
cause/effect in inducing human tumours by SV-40. SV-
40 DNA and expression of its oncogene, the large T anti-
gen, should be analysed in UM specimens to confirm
and extend the potential role of this oncogenic virus in
UM onset/progression. We should also consider, as an
alternative explanation, that another not yet discovered
human Polyomavirus closely related to SV-40 may be re-
sponsible of our immunologic data. Our results from the
laboratory bench could be transferred to the clinical
application employing specific innovative therapies for
SV40-positive UM patients.
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